Risk of complications from bone metastases in breast cancer: Implications for management

European Journal of Cancer

Volumn 36, Issue 4, 2000, Pages 476-482

  Plunkett, T A ^a   Smith, P ^a   Rubens, R D ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Radiotherapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RISK ASSESSMENT; SOFT TISSUE CANCER; SPINAL CORD COMPRESSION;

BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FRACTURES, BONE; HUMANS; HUMERAL FRACTURES; LIVER NEOPLASMS; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 0034051908     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00331-7     Document Type: Article

References (17)

1. Galasko C. The anatomy and pathways of bone metastases. Weiss L., Gilbert A. Bone Metastases. 1981;49-63 GK Hall, Boston.
2. Coleman R., Rubens R. The clinical course of bone metastases in breast cancer. Br. J. Cancer. 77:1987;336-340.
3. Kanis J. Bone and cancer. pathophysiology and treatment of metastases Bone. 17(Suppl.):1995;101S-105S.
4. Rodan G., Fleisch H. Bisphosphanates. mechanism of action J. Clin. Invest. 97:1996;2692-2696.
5. Hortobagyi G., Theriault R., Porter L.et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335:1996;1785-1791.
6. Hortobagyi G., Theriault R., Lipton A.et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:1998;2038-2044.
7. Theriault R., Lipton A., Hortobagyi G.et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions. a randomized, placebo-controlled trial J. Clin. Oncol. 17:1999;846-854.
8. Hillner B, Weeks J, Smith T, Desch C. Pamidronate in prevention of bone complications in metastatic breast cancer: a post-hoc cost-effectiveness analysis. Breast Cancer Treat Res 1998, 50, Abstract 31.
9. Hayward J., Carbone P., Heuson J.et al. Assessment of response to therapy in advanced breast cancer. Cancer. 39:1977;1289-1294.
10. Mirels H. Metastatic disease in long bones. a proposed scoring system for diagnosing impending pathological fractures Clin. Orthoped. Clin. Res. 249:1989;256-264.
11. Kanis J., McCloskey E., Powles T., Paterson A., Ashley S., Spector T. A high incidence of vertebral fracture in women with breast cancer. Br. J. Cancer. 79:1999;1179-1181.
12. Rivkees A., Crawford J. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 259:1988;2123-2125.
13. Saarto T., Blomqvist C., Valimaki M., Makelo P., Sarna S., Elooma I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate. a randomised study in premenopausal breast cancer patients J. Clin. Oncol. 15:1997;1341-1347.
14. Powles T., McCloskey E., Paterson A., Ashley S., Tidy A., Kanis J. The effect of tamoxifen on lumbar bone mineral density in pre- and post-menopausal women. J. Clin. Oncol. 14:1996;78-84.
15. Taube T., Elomaa I., Blomqvist C., Beneton M., Kanis J. Histomorphometric evidence for osteoclast mediated bone resorption in metastatic breast cancer. Bone. 15:1994;161-166.
16. Bouizar Z., Spyratos F., Deytieux S., Varnejoul M-C., Jullienne A. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res. 53:1993;5076-5078.
17. Guise T., Yin J., Taylor S., Kumagai Y., Dallas M., Boyce B., Yoneda T., Mundy G. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98:1996;1544-1549.